Home > News > Starpharma Pooled Development - half year report and accounts
February 25th, 2004
Starpharma Pooled Development - half year report and accounts
Abstract:
The results for the half year include a 42% reduction in the operating loss of the economic entity during the period, compared with the corresponding period of the previous year. Whilst part of this improvement has resulted from the successful conversion of the former controlled entity Dendritic Nanotechnologies Ltd to a US incorporated associated entity (Dendritic Nanotechnologies, Inc), two thirds of the savings are attributable to reductions in expenditure by the Australian group, as set out in the report.
Source:
Starpharma
Bookmark:
| Related News Press |
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||